Overview Dividends

(EOLS) Evolus - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30052C1071

Botulinum Toxin, Hyaluronic Acid Injectables

Pharmaceuticals
Market Cap in USD: 444m
IPO / Inception: 2018-02-08
Return 12m vs S&P 500: -48.3%

EPS (Earnings per Share)

EPS (Earnings per Share) of EOLS over the last years for every Quarter: "2020-12": -0.44, "2021-03": -0.2, "2021-06": -0.19, "2021-09": -0.27, "2021-12": -0.22, "2022-03": -0.22, "2022-06": -0.28, "2022-09": -0.28, "2022-12": -0.14, "2023-03": -0.15, "2023-06": -0.19, "2023-09": -0.16, "2023-12": -0.12, "2024-03": -0.09, "2024-06": -0.04, "2024-09": -0.16, "2024-12": 0.0139, "2025-03": -0.17, "2025-06": -0.27, "2025-09": -0.1478,
EPS CAGR: 19.49%
EPS Trend: 43.1%
Last SUE: -0.02
Qual. Beats: 0

Revenue

Revenue of EOLS over the last years for every Quarter: 2020-12: 20.577, 2021-03: 12.241, 2021-06: 26.098, 2021-09: 26.677, 2021-12: 34.657, 2022-03: 33.908, 2022-06: 37.163, 2022-09: 33.899, 2022-12: 43.646, 2023-03: 41.721, 2023-06: 49.346, 2023-09: 50.019, 2023-12: 60.999, 2024-03: 59.333, 2024-06: 66.909, 2024-09: 61.085, 2024-12: 78.947, 2025-03: 68.522, 2025-06: 69.387, 2025-09: 68.967,
Rev. CAGR: 20.14%
Rev. Trend: 94.7%
Last SUE: 0.30
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 56.1%
Value at Risk 5%th 77.7%
Relative Tail Risk -15.81%
Reward TTM
Sharpe Ratio -0.52
Alpha -57.10
CAGR/Max DD -0.08
Character TTM
Hurst Exponent 0.539
Beta 1.238
Beta Downside 1.354
Drawdowns 3y
Max DD 67.01%
Mean DD 25.81%
Median DD 22.30%

Description: EOLS Evolus December 26, 2025

Evolus, Inc. (NASDAQ:EOLS) is a cash-pay aesthetic-beauty company that markets its products in the United States, Canada, Europe, and Australia. Its flagship offering is Jeuveau, a 900-kilodalton purified botulinum toxin type A indicated for temporary reduction of moderate-to-severe glabellar lines, complemented by the Evolysse line of injectable hyaluronic-acid gels.

Key performance metrics from the most recent 10-Q (Q3 2024) show net sales of $84.3 million, a 12% year-over-year increase driven primarily by higher Jeuveau volume, and an adjusted EBITDA margin of roughly 22%, indicating a relatively high-margin business within the aesthetic sector.

The cash-pay aesthetic market is expanding at an estimated 7–9% CAGR globally, propelled by rising disposable income, increasing consumer acceptance of non-surgical cosmetic procedures, and a demographic shift toward younger adults seeking preventative treatments. Evolus’s reliance on a single proprietary neuromodulator makes product-line concentration a material risk that investors should monitor.

For a deeper quantitative assessment of Evolus’s valuation dynamics, you may find ValueRay’s analyst toolkit useful as a next step in your research.

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (-58.6m TTM) > 0 and > 6% of Revenue (6% = 17.1m TTM)
FCFTA -0.26 (>2.0%) and ΔFCFTA -14.49pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 23.85% (prev 36.06%; Δ -12.21pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.23 (>3.0%) and CFO -50.3m > Net Income -58.6m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 2.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (64.7m) change vs 12m ago 2.50% (target <= -2.0% for YES)
Gross Margin 65.83% (prev 68.14%; Δ -2.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 127.4% (prev 108.2%; Δ 19.28pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -1.80 (EBITDA TTM -29.3m / Interest Expense TTM 20.3m) >= 6 (WARN >= 3)

Altman Z'' -11.70

(A) 0.31 = (Total Current Assets 134.9m - Total Current Liabilities 66.7m) / Total Assets 219.0m
(B) -3.02 = Retained Earnings (Balance) -661.2m / Total Assets 219.0m
warn (B) unusual magnitude: -3.02 — check mapping/units
(C) -0.16 = EBIT TTM -36.5m / Avg Total Assets 224.3m
(D) -2.67 = Book Value of Equity -661.3m / Total Liabilities 247.8m
Total Rating: -11.70 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 28.86

1. Piotroski 2.0pt
2. FCF Yield -10.15%
3. FCF Margin -19.72%
4. Debt/Equity -5.39
5. Debt/Ebitda -3.80
6. ROIC - WACC (= -38.90)%
7. RoE 483.0%
8. Rev. Trend 94.72%
9. EPS Trend 43.07%

What is the price of EOLS shares?

As of December 30, 2025, the stock is trading at USD 6.66 with a total of 742,236 shares traded.
Over the past week, the price has changed by -7.37%, over one month by -2.35%, over three months by +8.47% and over the past year by -38.84%.

Is EOLS a buy, sell or hold?

Evolus has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy EOLS.
  • Strong Buy: 4
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the EOLS price?

Issuer Target Up/Down from current
Wallstreet Target Price 18.5 177.8%
Analysts Target Price 18.5 177.8%
ValueRay Target Price 6.2 -7.4%

EOLS Fundamental Data Overview December 27, 2025

Market Cap USD = 444.0m (444.0m USD * 1.0 USD.USD)
P/E Forward = 19.5695
P/S = 1.5535
P/B = 53.7058
Beta = 0.873
Revenue TTM = 285.8m USD
EBIT TTM = -36.5m USD
EBITDA TTM = -29.3m USD
Long Term Debt = 145.8m USD (from longTermDebt, last quarter)
Short Term Debt = 2.48m USD (from shortTermDebt, last quarter)
Debt = 154.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 111.4m USD (from netDebt column, last quarter)
Enterprise Value = 555.4m USD (444.0m + Debt 154.9m - CCE 43.5m)
Interest Coverage Ratio = -1.80 (Ebit TTM -36.5m / Interest Expense TTM 20.3m)
FCF Yield = -10.15% (FCF TTM -56.4m / Enterprise Value 555.4m)
FCF Margin = -19.72% (FCF TTM -56.4m / Revenue TTM 285.8m)
Net Margin = -20.49% (Net Income TTM -58.6m / Revenue TTM 285.8m)
Gross Margin = 65.83% ((Revenue TTM 285.8m - Cost of Revenue TTM 97.7m) / Revenue TTM)
Gross Margin QoQ = 66.47% (prev 65.31%)
Tobins Q-Ratio = 2.54 (Enterprise Value 555.4m / Total Assets 219.0m)
Interest Expense / Debt = 2.64% (Interest Expense 4.09m / Debt 154.9m)
Taxrate = -1.07% (negative due to tax credits) (167.0k / -15.6m)
NOPAT = -36.9m (EBIT -36.5m * (1 - -1.07%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 2.02 (Total Current Assets 134.9m / Total Current Liabilities 66.7m)
Debt / Equity = -5.39 (negative equity) (Debt 154.9m / totalStockholderEquity, last quarter -28.8m)
Debt / EBITDA = -3.80 (negative EBITDA) (Net Debt 111.4m / EBITDA -29.3m)
Debt / FCF = -1.98 (negative FCF - burning cash) (Net Debt 111.4m / FCF TTM -56.4m)
Total Stockholder Equity = -12.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.74% (Net Income -58.6m / Total Assets 219.0m)
RoE = 483.0% (negative equity) (Net Income TTM -58.6m / Total Stockholder Equity -12.1m)
RoCE = -27.32% (EBIT -36.5m / Capital Employed (Equity -12.1m + L.T.Debt 145.8m))
RoIC = -30.37% (negative operating profit) (NOPAT -36.9m / Invested Capital 121.5m)
WACC = 8.53% (E(444.0m)/V(598.9m) * Re(10.58%) + D(154.9m)/V(598.9m) * Rd(2.64%) * (1-Tc(-0.01)))
Discount Rate = 10.58% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.33%
Fair Price DCF = unknown (Cash Flow -56.4m)
EPS Correlation: 43.07 | EPS CAGR: 19.49% | SUE: -0.02 | # QB: 0
Revenue Correlation: 94.72 | Revenue CAGR: 20.14% | SUE: 0.30 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.07 | Chg30d=-0.043 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=0.17 | Chg30d=-0.074 | Revisions Net=-1 | Growth EPS=+143.3% | Growth Revenue=+19.3%

Additional Sources for EOLS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle